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Abstract
Left ventricular hypertrophy (LVH) occurs in 12% to 30% of patients with cirrhosis; however, its 
prognostic significance is not well studied. We assessed the association of LVH with survival in 
patients undergoing a liver transplantation (LT) evaluation. We performed a multicenter cohort 
study of patients undergoing an evaluation for LT. LVH was defined with transthoracic 
echocardiography. The outcome of interest was all-cause mortality. LVH was present in 138 of 
485 patients (28%). Patients with LVH were older, more likely to be male and African American, 
and were more likely to have hypertension. Three hundred forty-five patients did not undergo 
transplantation (212 declined, and 133 were waiting): 36 of 110 patients with LVH (33%) died, 
whereas 57 of 235 patients without LVH (24%) died (P = 0.23). After LT, 8 of 28 patients with 
LVH (29%) died over the course of 3 years, whereas 9 of 112 patients without LVH (8%) died (P 
= 0.007). This finding was independent of conventional risk factors for LVH, and all deaths for 
patients with LVH occurred within 9 months of LT. No clinical or demographic characteristics 
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were associated with mortality among LVH patients. In conclusion, the presence of LVH is 
associated with an early increase in mortality after LT, and this is independent of conventional risk 
factors for LVH. Further studies are needed to confirm these findings and identify factors 
associated with mortality after transplantation to improve outcomes.
Left ventricular hypertrophy (LVH) occurs in 12% to 30% of patients with cirrhosis.1,2 LVH 
appears to result in response to the hyperdynamic circulation and involves myocardial 
remodeling likely related to the activation of the renin-angiotensin-aldosterone axis and the 
increased levels of circulating bile salts, cytokines, and endotoxins in liver disease.3-6 LVH 
in patients with cirrhosis may be accompanied by diastolic impairment, electrophysiological 
abnormalities, and a decline in systolic function—a constellation of signs called cirrhotic 
cardiomyopathy.4,7
LVH is found in 11% to 14% of the general population and is associated with older age, 
African American race, male sex, hypertension, a greater body mass index (BMI), and 
diabetes.8-10 The presence of LVH increases the risks for cardiovascular events and 
mortality in the general population and in those with hypertension, end-stage renal disease, 
and valvular heart disease.11-16 In addition, the presence of LVH increases mortality after 
renal transplantation.17,18
The prevalence of preexisting cardiovascular risk factors for LVH has increased in the 
cirrhotic population.19,20 However, whether LVH increases mortality for patients 
undergoing an evaluation for liver transplantation (LT) and specifically for those undergoing 
LT is unknown. The aim of this study was to determine whether LVH influences mortality 
in a multicenter cohort of patients with cirrhosis undergoing an evaluation for LT.
Patients and Methods
Study Population
The Pulmonary Vascular Complications of Liver Disease study enrolled patients evaluated 
for LT at 7 centers in the United States between 2003 and 2006. The study included 
clinically stable outpatients undergoing an evaluation for LT because of portal hypertension 
with or without primary intrinsic liver disease. Patients were excluded if they had previously 
undergone liver or lung transplantation. Patients underwent transthoracic echocardiography 
as part of their LT evaluation. The study sample included patients with available 
echocardiography with an interpretable left ventricular mass. The study was approved by the 
institutional review board of each center, and all patients provided informed consent before 
they were enrolled into the study.
Data Collection and Variables
All patients underwent a comprehensive physical examination and laboratory assessment at 
their evaluation for LT. The Model for End-Stage Liver Disease (MELD) score was 
determined. Routine echocardio-graphic measures were obtained at accredited laboratories 
and were evaluated by American College of Cardiology/American Heart Association level 
III– trained physicians. LVH was diagnosed by the study centers on the basis of posterior 
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wall and interventricular septal thickness as observed on a parasternal long-axis view 
according to the criteria used in routine clinical practice.21 The survival and LT status and 
dates were obtained from medical records, the subjects' physicians, the subjects themselves, 
and the Social Security Death Index as of December 31, 2006. Patients who were alive were 
censored at this date.
Statistical Analyses
Continuous data were summarized as medians and interquartile ranges, and comparisons 
between patients with LVH and patients without LVH were made with the Wilcoxon rank-
sum test. Categorical data were reported as frequencies and percentages and were compared 
with Fisher's exact test.
The Kaplan-Meier product limit method and log-rank tests were used to determine 
differences in survival. Bivariate and multivariate Cox proportional hazard models were 
used to assess the association of LVH with the risk of death. Multiple imputations were 
performed for missing data before the multivariate analysis was performed. In the final 
multivariate model, we adjusted for variables that changed the coefficient of LVH by ≥15%, 
and we forced the following into the model: age, sex, race, BMI, MELD score, center, 
hypertension, and diabetes.
Covariates of interest that were evaluated for confounding included the following: 
demographics, severity of liver disease, complications of liver disease, etiology of liver 
disease, comorbidities, functional status [New York Heart Association (NYHA) functional 
class], and chronic kidney disease stage at the baseline transplant evaluation. The chronic 
kidney disease stage was determined with the estimated glomerular filtration rate from the 
Modification of Diet in Renal Disease equation.
The analysis of transplant-free survival was performed through the censoring of 
observations at the time of transplantation or last follow-up. Analyses of overall mortality 
were evaluated with adjustments for LT as a time-varying covariate.
Results
Five hundred thirty-six patients were enrolled in the Pulmonary Vascular Complications of 
Liver Disease study between 2003 and 2006. The study sample consisted of 485 patients 
with available and interpretable echocardiography. LVH was diagnosed in 138 patients 
(28%). Patients with LVH were older; were more often male and African American; more 
commonly had nonalcoholic fatty liver disease, hypertension, diabetes, and cardiopulmonary 
symptoms; and more often were using angiotensin-converting enzyme inhibitors (Table 1). 
Sixty-four percent of the LVH patients had predisposing risk factors for LVH (hypertension, 
diabetes, and African American race). Patients with LVH had higher systolic (P = 0.007) 
and diastolic blood pressures (P = 0.001) than those without LVH, although these 
differences were clinically insignificant. Patients with LVH were similar to those without 
LVH with respect to the severity of liver disease (the MELD score), the history and severity 
of complications of portal hypertension (variceal bleeding, ascites, and hepatocellular 
Batra et al. Page 3






















carcinoma), ischemic heart disease, valvular heart disease, and the use of beta-blockers or 
diuretics.
During a median follow-up period of 20 months (interquartile range = 13-25 months) and 
787 person-years of observation for the 485 patients evaluated for LT, 140 patients (29%) 
underwent transplantation, 93 (19%) died without transplantation, and 252 (52%) had not 
undergone transplantation as of December 31, 2006 (including 145 patients not listed for 
LT; Fig. 1). The 6- and 12-month overall cumulative survival rates were 92% [95% 
confidence interval (CI) = 89%-94%] and 86% (95% CI = 82%-88%), respectively.
There was no significant association between LVH and overall mortality (including post-LT 
survival) after adjustments for age, sex, race, and center [hazard ratio (HR) = 1.02 
(0.61-1.72), P = 0.92; Fig. 2]. However, there was an apparent interaction between LVH and 
LT in terms of outcomes (P for interaction = 0.055). LT recipients and nonrecipients were 
similar in terms of age, sex, race, BMI, liver disease etiology, echocardio-graphic features, 
NYHA grade, and beta-blocker or diuretic use (Table 2). Although the presence of LVH was 
similar in the 2 groups, LT recipients were less often hypertensive (P = 0.046) or diabetic (P 
= 0.049) and had fewer cardiovascular symptoms than nonrecipients. LT recipients did have 
more severe and complicated liver disease than nonrecipients.
Among the nonrecipients, the 1-year mortality rates were similar for those with LVH [25% 
(95% CI: 18%- 34%)] and those without LVH [14%: 95% CI: (10%-19%); log-rank P for 
overall survival = 0.23; Fig. 3A)]. In contrast, LT recipients with LVH had a 1-year post-LT 
risk of death of 30% (16%-51%), whereas the 1-year post-LT risk of death was 7% 
(3%-14%) for those without LVH (log-rank P for overall post-LT survival = 0.002; Fig. 3B). 
A multivariate analysis revealed an approximately 4-fold greater risk for mortality after LT 
for those with LVH versus those without LVH (Table 3). Furthermore, an additional 
sensitivity analysis found no effect from excluding the single patient with portopulmonary 
hypertension who underwent LT on the aforementioned association (HR= 3.89, 95% CI = 
1.45-10.3). When we adjusted for the potential variation between centers, we found that the 
association between LVH and post-LT mortality became stronger because of negative 
confounding by intercenter variations (HR = 5.92, 95% CI = 1.82-19.17). All deaths of LVH 
patients occurred within 9 months of LT.
Exploratory subgroup analyses showed no differences in demographic and clinical features 
between LT recipients with LVH and LT recipients without LVH (Table 4). Furthermore, 
there were no significant predictors of mortality for the patients with LVH who underwent 
LT (data not shown).
Discussion
In a multicenter cohort of patients being evaluated for LT, we showed that LVH was 
associated with an approximately 4-fold increase in mortality after LT. This finding was 
independent of the presence of conventional risk factors for LVH and other potential con-
founders. The presence of LVH did not appear to affect the survival of patients who did not 
undergo LT (or the survival of patients before they underwent LT). A subgroup analysis of 
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patients with LVH who underwent LT revealed no baseline clinical or demographic 
characteristic associated with post-LT mortality. A similar association of LVH with 
postoperative cardiac events in major surgical procedures, including renal transplantation, 
has been previously observed.17,18,22 The current study provides the first evidence 
demonstrating an association between LVH and mortality in patients with cirrhosis 
undergoing LT.
LVH was diagnosed in 28% of the patients evaluated for LT in our cohort. Our estimates are 
similar to those of previous studies, which have reported a prevalence of LVH of 12% to 
30% in patients with cirrhosis.1,2,23,24 Although we found that the majority of the LVH 
patients had preexisting risk factors for LVH, 36% did not. Similar observations were made 
by Lunseth et al.23 in an autopsy study of patients with cirrhosis: LVH was found in 33% of 
patients without pathological evidence of hypertension, atherosclerosis, or other structural 
cardiac abnormalities. This suggests that both cirrhosis and conventional risk factors for 
LVH contribute to an increase in the left ventricular mass.
The approximately 4-fold increased risk for post-LT mortality in patients with LVH was 
observed despite adjustments for confounding by conventional risk factors for LVH, 
demographics, and severity of liver disease (MELD score). Furthermore, post-LT deaths of 
patients with LVH occurred early after LT. One potential explanation for this finding is a 
higher risk of peri-operative complications with LVH. However, we do not have detailed 
data regarding events surrounding LT in this cohort. Multiple mechanisms may underlie the 
cardiac dysfunction associated with LVH, including demand ischemia, arrhythmias, 
accelerated atherogenesis, and diastolic dysfunction.25-27 The presence of diastolic 
dysfunction has been observed to increase the risk of congestive heart failure after LT28 and 
has been associated with increased mortality after trans-jugular intrahepatic portosystemic 
shunting.29,30 The impact of LVH before and after LT may also be influenced by medical 
therapies. For instance, the use of high-dose steroids and calcineurin inhibitors early after 
LT could exacerbate the impact of LVH and potentially explain why LVH influenced 
outcomes only after LT. In contrast, the use of beta-blockers and diuretics in the setting of 
low systemic vascular resistance before (or without) LT may diminish hemodynamic 
stresses on the heart and mitigate the cardiovascular consequences of LVH.
There are several limitations to this study. First, we included only patients evaluated for LT, 
and our findings may not be generalizable to all patients with cirrhosis. Second, we cannot 
eliminate the possibility that the exclusion of patients due to missing echocar-diographic or 
clinical data may have influenced our findings. However, the excluded patients with missing 
data were similar to the study cohort with respect to the recorded variables, and this lessened 
the chance of a selection bias (data not shown). Third, there might be differences in the 
criteria used to define LVH between centers that could have influenced the relationship with 
post-LT mortality.31,32 However, any variability in interpretation across centers would likely 
have resulted in a nondifferential measurement error that would have biased our findings to 
the null and thereby reduced any observed association between LVH and outcomes (unless 
the differential classification depended on outcomes; this is difficult to conceive because 
echocardiography was performed before any outcomes occurred). In line with this concept, 
we found an increase in the HR for the association of LVH with post-LT mortality when we 
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accounted for centers in our multivariate analysis. Fourth, the exclusion of patients who 
were not listed for LT could potentially have influenced post-LT outcomes through the 
introduction of a selection bias. However, LVH patients who were not listed had a higher 
prevalence of congestive heart failure, hypertension, and chronic obstructive pulmonary 
disease than the listed LVH and control patients (Supporting Table 1). The exclusion of 
these patients would have been expected to diminish the differences in post-LT survival 
between the LVH and non-LVH groups and bias the results to the null. Finally, we did not 
collect information on the causes of death, and this potentially limited the evaluation of how 
LVH contributes to mortality. However, determining whether any particular cause of death 
is causally related to underlying LVH may not be possible. Nonetheless, this is the first large 
multicenter cohort study to demonstrate an association between LVH and post-LT mortality, 
and it supports the idea that the mechanisms for this effect require further investigation.
We observed an approximately 4-fold increase in post-LT mortality in patients with 
cirrhosis and LVH versus those without LVH in a large multicenter cohort, and this was 
independent of conventional risk factors for LVH. The temporal association of mortality 
with the time frame of recognized hemodynamic changes after LT raises the possibility that 
cardiac dysfunction may play a role. Whether increased vigilance in the follow-up of such 
patients in the early postoperative period may improve outcomes is not known. Further 
studies are needed to confirm these findings and to define the precise mechanisms involved 
in order to eliminate the adverse consequences of LVH on transplant outcomes.
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Selection and outcomes of the study population.
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Comparison of the survival of evaluated patients with LVH and evaluated patients without 
LVH. The survivor functions have been adjusted for race, sex, age, BMI, MELD score, 
hypertension, and diabetes mellitus. [Color figure can be viewed in the online issue, which is 
available at wileyonlinelibrary.com.]
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(A) Comparison of the survival of patients with LVH and patients without LVH censored at 
the time of LT (patients not listed for LT are included). (B) Comparison of the post-LT 
survival of patients with LVH and patients without LVH. [Color figure can be viewed in the 
online issue, which is available at wileyonlinelibrary.com.]
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Table 1
Study Sample
Sample Size (n) LVH (n = 138) No LVH (n5347) P Value
Age (years)* 485 56 (50-61) 52 (47-58) <0.001
Male [n (%)] 485 98 (71) 194 (56) 0.002
BMI (kg/m2)* 483 30 (26-34) 28 (24-32) 0.001
Race [n (%)] 485 <0.001
 Non-Hispanic white 119 (86) 280 (81)
 African American 12 (9) 10 (3)
 Hispanic white 4 (3) 34 (10)
 Other 3 (2) 23 (7)
Etiology [n (%)] 485
 Alcohol 57 (41) 138 (40) 0.76
 Nonalcoholic fatty liver disease 20 (14) 29 (8) 0.047
 Hepatitis C virus 55 (40) 147 (42) 0.68
 Other 54 (39) 109 (31) 0.11
Comorbid conditions [n (%)]
 Hypertension 483 60 (43) 81 (23) <0.001
 Diabetes mellitus 482 51 (37) 96 (28) 0.06
 Coronary artery disease 483 9 (7) 6 (2) 0.38
 Left ventricular dysfunction 478 26 (19) 4 (1) 0.06
 Stage IV-V chronic kidney disease 485 7 (5) 10 (3) 0.27
Blood pressures (mm Hg)*
 Systolic 483 123 (110-137) 118 (106-130) 0.007
 Diastolic 483 71 (65-80) 68 (60-78) 0.001
MELD score* 479 14 (10-17) 13 (10-17) 0.73
Complications of liver disease [n (%)]
 Hepatocellular carcinoma 484 10 (7) 27 (8) 1.00
 Ascites 481 68 (49) 156 (45) 0.42
 Variceal bleed 484 34 (25) 73 (21) 0.39
Echocardiography [n (%)]
Left atrial size (cm)* 405 4.1 (3.8-4.5) 4 (3.6-4.6) 0.16
Aortic regurgitation: moderate to severe [n (%)] 474 5 (1) 2 (1) 1.00
Mitral regurgitation: moderate to severe [n (%)] 471 7 (5) 11 (3) 0.29
Symptoms [n (%)]
 Orthopnea 465 30 (22) 31 (9) <0.001
 Palpitation 471 29 (21) 32 (9) 0.001
 Dyspnea 481 56 (41) 127 (37) 0.34
NYHA functional status grade III or higher [n (%)] 484 45 (33) 92 (27) 0.18
Medications [n (%)]
 Beta-blockers 485 56 (41) 144 (41) 0.91
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Sample Size (n) LVH (n = 138) No LVH (n5347) P Value
 Angiotensin-converting enzyme inhibitors 483 16 (12) 19 (5) 0.03
 Diuretics 485 69 (50) 202 (58) 0.10
*
The data are presented as medians and interquartile ranges.
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Table 2
Demographic and Clinical Characteristics of the Study Population by Transplantation 
Status
Sample Size (n) Nontransplant Patients (n = 
345)
Transplant Patients (n = 
140)
P Value
Age (years)* 485 53 (48-59) 54 (48-60) 0.62
Male [n (%)] 485 199 (58) 93 (66) 0.08
BMI (kg/m2)* 483 29 (25-33) 28 (24-31) 0.18
Race [n (%)] 485 0.69
 African American 15 (4) 7 (5)
 Non-Hispanic white 288 (83) 111 (79)
 Hispanic white 25 (7) 13 (9)
 Other 17 (5) 9 (6)
Etiology of liver disease [n (%)] 485
 Alcohol 143 (41) 52 (37) 0.41
 Nonalcoholic fatty liver disease 33 (10) 16 (11) 0.51
 Hepatitis C virus 143 (41) 59 (42) 0.91
 Other 120 (35) 43 (31) 0.46
Comorbid conditions [n (%)]
 Hypertension 483 110 (32) 31 (22) 0.046
 Diabetes mellitus 482 114 (33) 33 (24) 0.049
 Chronic obstructive pulmonary disease 483 27 (8) 8 (6) 0.56
 Coronary artery disease 483 13 (4) 2 (1) 0.25
 Left ventricular dysfunction 478 21 (6) 9 (6) 0.84
 Stage IV-V chronic kidney disease 484 8 (2) 9 (6) 0.052
Blood pressures (mm Hg)*
 Systolic 483 120 (110-132) 117 (104-129) 0.029
 Diastolic 483 70 (62-79) 68 (60-75) 0.045
MELD score* 479 12 (10-16) 14 (11-18) <0.001
Complications of cirrhosis [n (%)]
 Hepatocellular carcinoma 484 19 (6) 18 (13) 0.008
 Ascites 477 118 (34) 69 (49) 0.003
 Variceal bleed 484 78 (23) 29 (21) 0.71
 Encephalopathy 483 138 (40) 67 (48) 0.13
Echocardiography [n (%)]
Left atrial size (cm)* 405 4.1 (3.7- 4.5) 4.1 (3.6-4.5) 0.79
Aortic regurgitation [n (%)] 473 86 (25) 32 (23) 0.72
Aortic regurgitation: moderate to severe [n (%)] 473 4 (1) 2 (1) 1.00
Mitral regurgitation: moderate to severe [n (%)] 471 14 (4) 4 (3) 0.8
LVH [n (%)] 485 110 (32) 28 (20) 0.10
Symptoms [n (%)]
 Palpitation 471 53 (15) 8 (6) 0.004
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Sample Size (n) Nontransplant Patients (n = 
345)
Transplant Patients (n = 
140)
P Value
 Orthopnea 465 47 (14) 14 (10) 0.44
 Dyspnea 481 137 (40) 46 (33) 0.21
NYHA functional status III or higher [n (%)] 484 104 (30) 33 (24) 0.15
Medications [n (%)]
 Beta-blockers 485 147 (43) 53 (38) 0.36
 Angiotensin-converting enzyme inhibitors 483 30 (9) 5 (4) 0.05
 Diuretics 485 193 (56) 78 (56) 1.00
Deaths [n (%)] 485 93 (27) 17 (12) <0.001
*
The data are presented as medians and interquartile ranges.
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Table 3
Posttransplant Mortality (n = 140)
HR 95% CI P Value
LVH adjusted for age, sex, race, and BMI 3.72 1.39-10.00 0.009
LVH adjusted for age, sex, race, BMI, and MELD score 3.73 1.39-10.05 0.009
LVH adjusted for age, sex, race, BMI, MELD score, and center 5.92 1.82-19.17 0.003
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Table 4
Transplant Population
Sample Size (n) LVH (n = 28) No LVH (n = 112) P Value
Age (years)* 140 57 (52-61) 53 (47-60) 0.14
Male [n (%)] 140 21 (75) 72 (64) 0.37
BMI (kg/m2)* 140 28 (26-32) 28 (24-31) 0.28
Race [n (%)] 140 0.19
 African American 3 (11) 4 (4)
 Non-Hispanic white 23 (82) 88 (79)
 Hispanic white 2 (7) 11 (10)
 Other race 0 (0) 9 (8)
Etiology of liver disease [n (%)] 140
 Alcohol 14 (50) 38 (34) 0.13
 Nonalcoholic fatty liver disease 5 (18) 11 (10) 0.31
 Hepatitis C virus 9 (32) 50 (45) 0.29
 Other 12 (43) 31 (28) 0.17
Comorbid conditions [n (%)]
 Hypertension 138 8 (29) 23 (20) 0.45
 Diabetes mellitus 138 9 (32) 24 (21) 0.32
 Coronary artery disease 138 0 (0) 2 (2) 1.00
 Left ventricular dysfunction 138 9 (8) 0 (0) 0.20
 Stage IV-V chronic kidney disease 140 3 (11) 6 (5) 0.38
Blood pressures (mm Hg)*
 Systolic 140 120 (105-136) 116 (103-128) 0.24
 Diastolic 140 68 (62-72) 68 (60-76) 0.93
MELD score* 137 14 (11-19) 14.5 (11-18) 0.98
Complications of liver disease [n (%)]
 Hepatocellular carcinoma 140 4 (14) 14 (12) 0.76
 Ascites 139 15 (54) 60 (54) 1.00
 Variceal bleed 140 7 (25) 22 (20) 0.6
 Portopulmonary hypertension 71 0 (0) 1 (0.9) 1.00
Right ventricular hypertrophy [n (%)] 139 8 (29) 5 (4) 0.001
Symptoms [n (%)]
 Palpitation 133 3 (11) 5 (4) 0.17
 Orthopnea 129 5 (18) 9 (8) 0.14
 Dyspnea 137 8 (29) 38 (34) 1.00
NYHA functional status III or higher [n (%)] 140 8 (29) 25 (22) 0.47
Medications [n (%)]
 Beta-blockers 140 9 (32) 44 (39) 0.52
 Angiotensin-converting enzyme inhibitors 138 2 (7) 3 (3) 0.27
 Diuretics 140 12 (43) 66 (59) 0.14
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Sample Size (n) LVH (n = 28) No LVH (n = 112) P Value
Deaths [n (%)] 140 8 (29) 9 (8) 0.007
*
The data are presented as medians and interquartile ranges.
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